Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 4 , Pages 615-623 , August 2008

The endocrine prevention of breast cancer

  • Anthony Howell, FRCP (Professor of Medical Oncology)

      Affiliations

    • Corresponding Author InformationCRUK Department of Medical Oncology, Christie Hospital, Manchester M20 4BX, UK. Tel.: +44 161 446 8037; Fax: +44 161 446 8000.

References 

  1. Howell A, Clarke RB, Evans G, et al. Estrogen deprivation for breast cancer prevention. Recent Results in Cancer Research. 2007;174:151–167
  2. Feinleib M. Breast cancer and artificial menopause: a cohort study. Journal of the National Cancer Institute. 1968;41:315–329
  3. Hirayama T, Wynder EL. A study of the epidemiology of cancer of the breast II. The influence of hysterectomy. Cancer. 1962;5:28–38
  4. Trichopoulos D, MacMahon B, Cole P. Menopause and breast cancer risk. Journal of the National Cancer Institute. 1972;48:605–613
  5. Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case control study. Hereditary Breast Cancer Clinical Study Group. Lancet. 2000;356:1876–1881
  6. Gronwald J, Tung N, Foulkes WD, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. International Journal of Cancer. 2006;118:2281–2284
  7. Rebbeck TR, Lynch HT, Neuhausen SL. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. The New England Journal of Medicine. 2002;346:1616–1622
  8. Kauff ND, Satagopan JM, Robson ME, et al. Risk reducing salpino-oophorectomy in women with a BRCA1 and BRCA2 mutation. The New England Journal of Medicine. 2002;346:1609–1615
  9. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Journal of Clinical Oncology. 2004;22:2328–2335
  10. Olson JE, Sellers TA, Iturria SJ, et al. Bilateral oophorectomy and breast cancer risk reduction among women with a family history. Cancer Detection and Prevention. 2004;28:357–360
  11. Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case control study. Journal of Clinical Oncology. 2005;23:7491–7496
  12. Cuzick J, Baum M. Tamoxifen and contralateral breast cancer. Lancet. 1985;2:282
  13. Early Breast Cancer Trialists' Collaborative Group . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717
  14. Cuzick J. Aromatase inhibitors for breast cancer prevention. Journal of Clinical Oncology. 2005;23:1636–1643
  15. Powles TJ, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998;352:98–101
  16. Powles TJ, Ashley S, Tidy VA, et al. 20 year follow up of the Royal Marsden tamoxifen breast cancer prevention trial. Journal of the National Cancer Institute. 2007;99(4):283–290
  17. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002;360:817–824
  18. Cuzick J, Forbes J, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer – 96 month follow up of the IBIS-I study. Journal of the National Cancer Institute. 2007;99(4):272–282
  19. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Journal of the National Cancer Institute. 1998;90:1371–1388
  20. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Journal of the National Cancer Institute. 2005;97:1652–1662
  21. Cummings SR, Eckert S, Krueger KA. The effect of Raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomised trial. JAMA : The Journal of the American Medical Association. 1999;281:2189–2197
  22. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to evista: breast cancer incidence in postmenopausal osteoporotic women in a randomised trial of raloxifene. Journal of the National Cancer Institute. 2004;96:1751–1761
  23. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. The New England Journal of Medicine. 2006;355:125–137
  24. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen versus raloxifene on the risk of developing invasive breast cancer and other disease outcomes. The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA : The Journal of the American Medical Association. 2006;295:2727–2741
  25. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast cancer prevention trials. Lancet. 2003;361:296–300
  26. Pike MC, Spicer DV. The chemoprevention of breast cancer by reducing sex steroid exposure: perspectives from epidemiology. Journal of Cellular Biochemistry. Supplement. 1993;17G:26–36
  27. Clarke RB, Howell A, Potten C, et al. Dissociation between steroid receptor expression and cell proliferation suggests cellular hierarchies in the human breast. Cancer Research. 1997;57:4987–4992
  28. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the women's health initiative randomized trial. JAMA : The Journal of the American Medical Association. 2003;289(24):3243–3253
  29. Armstrong K, Schwartz JS, Randall T, et al. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. Journal of Clinical Oncology. 2004;22:1045–1054
  30. Veronesi U, Maisonneuvre P, Rotmensz N, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian randomised tamoxifen prevention trial among women with hysterectomy. Journal of the National Cancer Institute. 1997;99:727–737
  31. Veronesi U, Maisonneuve P, Rotmensz N, et al. Italian randomised trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high risk women. Journal of the National Cancer Institute. 2003;95:160–165
  32. Decensi A, Galli A, Veronesi U. HRT opposed to low-dose tamoxifen (HOT study): rationale and design. Recent Results in Cancer Research. 2003;163:104–111

PII: S1521-690X(08)00100-0

doi: 10.1016/j.beem.2008.09.002

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 4 , Pages 615-623 , August 2008

Article Tools

* Image Usage & Resolution